On September 12, 2022, Michael Burgess, the Company's Head of Research and Development, notified SpringWorks Therapeutics, Inc. (the Company) that he will be retiring, effective September 16, 2022 (the Retirement Date). Dr. Burgess' retirement is not the result of any dispute or disagreement with the Company or the Board, or any matter relating to the Company's operations, policies or practices. In connection with Dr. Burgess' retirement, Dr. Burgess and the Company entered into a Consulting and Separation Agreement (the Consulting and Separation Agreement) pursuant to which Dr. Burgess will act as Senior Strategic Advisor to the Company, effective as of the day immediately following the Retirement Date.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.2 USD | +1.89% | +4.07% | +21.10% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.10% | 3.26B | |
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.12% | 22.02B | |
-17.84% | 20.9B | |
-9.33% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |
- Stock Market
- Equities
- SWTX Stock
- News SpringWorks Therapeutics, Inc.
- SpringWorks Therapeutics, Inc. Announces Resignation of Michael Burgess as the Head of Research and Development